Index -
P/E -
EPS (ttm) -2.19
Insider Own 18.89%
Shs Outstand 6.00M
Perf Week 5.90%
Market Cap 41.67M
Forward P/E -
EPS next Y -0.55
Insider Trans 3.79%
Shs Float 5.23M
Perf Month 6.43%
Income -14.22M
PEG -
EPS next Q -0.30
Inst Own 20.15%
Short Float 0.36%
Perf Quarter 2.87%
Sales 21.28M
P/S 1.96
EPS this Y 60.16%
Inst Trans -10.83%
Short Ratio 2.06
Perf Half Y 0.94%
Book/sh 1.78
P/B 3.63
EPS next Y 59.88%
ROA -77.78%
Short Interest 0.02M
Perf Year 18.75%
Cash/sh 2.24
P/C 2.88
EPS next 5Y -
ROE -153.49%
52W Range 4.90 - 8.08
Perf YTD 8.54%
Dividend Est. -
P/FCF -
EPS past 5Y 28.11%
ROI -94.19%
52W High -20.05%
Beta 0.62
Dividend TTM -
Quick Ratio 2.12
Sales past 5Y 77.42%
Gross Margin 83.61%
52W Low 31.84%
ATR (14) 0.25
Dividend Ex-Date -
Current Ratio 2.48
EPS Y/Y TTM 52.71%
Oper. Margin -67.63%
RSI (14) 61.26
Volatility 5.65% 3.39%
Employees 68
Debt/Eq 0.35
Sales Y/Y TTM 95.83%
Profit Margin -66.84%
Recom 1.00
Target Price 21.38
Option/Short No / Yes
LT Debt/Eq 0.32
EPS Q/Q 63.49%
Payout -
Rel Volume 4.47
Prev Close 6.00
Sales Surprise 9.68%
EPS Surprise 11.63%
Sales Q/Q 72.88%
Earnings Aug 07 AMC
Avg Volume 9.26K
Price 6.46
SMA20 7.32%
SMA50 6.84%
SMA200 2.16%
Trades
Volume 41,334
Change 7.65%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-20 Upgrade
BTIG Research
Neutral → Buy
$3.50
Nov-14-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Sep-26-19 Resumed
Cantor Fitzgerald
Neutral
$9
May-30-19 Downgrade
Cantor Fitzgerald
Overweight → Neutral
May-15-19 Downgrade
BTIG Research
Buy → Neutral
May-09-19 Initiated
Noble Capital Markets
Outperform
Sep-21-18 Initiated
Cantor Fitzgerald
Overweight
Sep-10-24 08:00AM
Sep-04-24 08:00AM
02:00AM
Aug-08-24 08:00AM
Aug-07-24 05:40PM
04:01PM
Loading…
04:01PM
Aug-02-24 04:05PM
Aug-01-24 08:00AM
Jul-31-24 08:00AM
Jun-25-24 08:00AM
Jun-11-24 08:00AM
Jun-06-24 01:00PM
08:00AM
Jun-03-24 08:30AM
May-30-24 09:55AM
09:00AM
Loading…
May-29-24 09:00AM
May-14-24 09:55AM
08:50AM
May-09-24 02:42PM
03:43AM
May-08-24 09:56PM
05:45PM
04:05PM
May-03-24 04:05PM
May-01-24 08:04AM
Apr-30-24 08:00AM
Apr-08-24 08:30AM
Apr-02-24 08:00AM
Mar-16-24 02:15PM
Mar-14-24 06:19AM
(Thomson Reuters StreetEvents) -5.58%
05:25PM
Loading…
Mar-13-24 05:25PM
04:05PM
Mar-12-24 08:00AM
Mar-05-24 04:05PM
Feb-06-24 08:00AM
Jan-09-24 08:00AM
Dec-26-23 08:00AM
Dec-21-23 04:13PM
Dec-12-23 08:00AM
Nov-15-23 08:15AM
Nov-09-23 01:17PM
Nov-08-23 06:29PM
04:01PM
Nov-07-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
Oct-10-23 08:00AM
Oct-09-23 08:00AM
Oct-05-23 08:00AM
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-25-23 08:30AM
08:00AM
Sep-21-23 08:00AM
Sep-07-23 08:00AM
Aug-23-23 08:00AM
Aug-11-23 01:41PM
06:46AM
Aug-10-23 07:39AM
(Thomson Reuters StreetEvents) -8.84%
Aug-09-23 04:05PM
Aug-04-23 07:14AM
Aug-01-23 08:00AM
Jul-31-23 09:29AM
Jul-25-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 06:03AM
(Zacks Small Cap Research)
Jul-13-23 08:00AM
Jul-11-23 08:00AM
Jul-06-23 08:00AM
Jun-27-23 08:00AM
Jun-14-23 08:00AM
Jun-13-23 08:00AM
May-26-23 04:01PM
May-23-23 08:00AM
May-04-23 06:33AM
(Zacks Small Cap Research) -5.00%
May-03-23 04:01PM
May-01-23 04:01PM
Apr-26-23 08:00AM
Apr-24-23 08:00AM
Apr-19-23 08:00AM
Apr-17-23 08:00AM
Apr-12-23 08:00AM
Apr-11-23 08:00AM
Apr-06-23 08:00AM
Apr-04-23 08:00AM
Mar-23-23 08:00AM
Mar-21-23 08:00AM
Mar-14-23 08:30AM
Mar-13-23 08:00AM
Mar-10-23 02:25AM
Mar-09-23 11:48AM
(Zacks Small Cap Research) +9.47%
08:00AM
Mar-08-23 04:05PM
Mar-07-23 08:00AM
Mar-01-23 08:00AM
Feb-21-23 08:00AM
Feb-16-23 08:00AM
Feb-15-23 08:00AM
07:01AM
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Errico Thomas J. Director Aug 15 '24 Buy 6.12 5,000 30,595 233,818 Aug 19 09:37 AM GANDOLFO JOHN P Director Jun 13 '24 Buy 6.43 1,000 6,430 50,704 Jun 17 04:05 PM Goldberger Daniel S Chief Executive Officer Jun 05 '24 Buy 6.43 38,505 247,587 249,565 Jun 06 08:30 AM
Index -
P/E -
EPS (ttm) -0.80
Insider Own 11.22%
Shs Outstand 76.91M
Perf Week -6.74%
Market Cap 38.49M
Forward P/E -
EPS next Y -0.52
Insider Trans 25.30%
Shs Float 68.28M
Perf Month 7.63%
Income -37.28M
PEG -
EPS next Q -0.12
Inst Own 15.24%
Short Float 2.93%
Perf Quarter -23.00%
Sales 0.03M
P/S 1283.12
EPS this Y 2.65%
Inst Trans -21.12%
Short Ratio 1.15
Perf Half Y -57.58%
Book/sh -0.04
P/B -
EPS next Y 19.46%
ROA -154.24%
Short Interest 2.00M
Perf Year -69.85%
Cash/sh 0.03
P/C 16.74
EPS next 5Y -
ROE -914.66%
52W Range 0.37 - 2.57
Perf YTD -75.94%
Dividend Est. -
P/FCF -
EPS past 5Y 18.26%
ROI -1184.92%
52W High -80.53%
Beta 1.74
Dividend TTM -
Quick Ratio 0.24
Sales past 5Y 100.00%
Gross Margin -5377.64%
52W Low 35.27%
ATR (14) 0.07
Dividend Ex-Date -
Current Ratio 0.43
EPS Y/Y TTM -15.29%
Oper. Margin -98956.56%
RSI (14) 36.15
Volatility 7.62% 11.79%
Employees 57
Debt/Eq -
Sales Y/Y TTM -99.99%
Profit Margin -118712.53%
Recom 1.00
Target Price 7.67
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -27.51%
Payout -
Rel Volume 0.59
Prev Close 0.50
Sales Surprise -97.53%
EPS Surprise -40.00%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 1.74M
Price 0.50
SMA20 -6.75%
SMA50 -40.96%
SMA200 -56.59%
Trades
Volume 1,027,748
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-21 Initiated
Northland Capital
Outperform
$10
Feb-03-20 Downgrade
Oppenheimer
Outperform → Perform
Sep-09-24 06:53AM
(Pharmaceutical Technology) +14.35%
03:00AM
Sep-05-24 07:00AM
Sep-03-24 07:00AM
Aug-23-24 11:42AM
09:29AM
Loading…
Aug-21-24 09:29AM
Aug-20-24 05:09PM
Aug-15-24 12:00PM
Aug-13-24 07:00AM
Aug-12-24 05:30PM
04:05PM
Aug-08-24 07:00AM
Aug-07-24 05:11PM
08:00AM
Jul-30-24 08:00AM
07:00AM
Loading…
Jul-23-24 07:00AM
Jul-01-24 06:50AM
Jun-28-24 08:00AM
May-23-24 06:00AM
May-20-24 12:00PM
May-16-24 03:07AM
May-15-24 08:55PM
04:01PM
May-14-24 07:00AM
May-10-24 06:31AM
(Pharmaceutical Technology)
Apr-25-24 07:00AM
Apr-09-24 09:29AM
Apr-08-24 07:00AM
Apr-03-24 07:00AM
Mar-27-24 11:28AM
09:57AM
Loading…
09:57AM
(Thomson Reuters StreetEvents)
Mar-19-24 08:50AM
06:41AM
(Thomson Reuters StreetEvents)
Mar-18-24 08:53PM
05:20PM
04:05PM
Mar-13-24 07:00AM
Mar-11-24 07:00AM
Mar-05-24 12:59PM
08:00AM
Mar-04-24 06:21PM
06:06PM
Feb-13-24 07:00AM
Jan-26-24 09:22AM
Jan-16-24 07:00AM
Dec-15-23 08:17AM
Nov-14-23 10:38AM
Nov-13-23 04:05PM
Nov-06-23 08:00AM
Nov-02-23 07:00AM
Oct-30-23 03:52PM
07:00AM
Oct-09-23 07:00AM
Sep-21-23 08:00AM
Sep-07-23 08:00AM
Aug-24-23 06:47PM
Aug-16-23 06:00AM
Aug-14-23 09:05AM
Aug-11-23 06:08AM
(Thomson Reuters StreetEvents)
Aug-10-23 04:05PM
Aug-09-23 08:00AM
Aug-07-23 08:00AM
Aug-03-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 09:00AM
Jun-01-23 08:00AM
May-12-23 06:04AM
(Thomson Reuters StreetEvents) -15.20%
May-11-23 04:05PM
May-08-23 04:39PM
08:17AM
08:02AM
08:00AM
02:32AM
May-04-23 08:00AM
Apr-24-23 08:00AM
Apr-05-23 07:46PM
Mar-30-23 04:05PM
Mar-23-23 08:00AM
Feb-28-23 04:05PM
Feb-22-23 06:08AM
Feb-15-23 09:51AM
Jan-12-23 12:47PM
08:00AM
Dec-20-22 08:00AM
Dec-13-22 08:00AM
Dec-08-22 08:00AM
Nov-29-22 08:00AM
Nov-23-22 04:05PM
Nov-13-22 07:04AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Oct-21-22 08:00AM
Oct-20-22 08:00AM
Oct-05-22 02:50PM
Sep-30-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-10-22 04:05PM
(GlobeNewswire) +5.42%
-5.14%
Aug-04-22 08:00AM
Jul-27-22 08:00AM
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rowe Michael M Chief Executive Officer Aug 28 '24 Buy 0.52 27,071 14,077 109,998 Aug 28 08:01 PM Rowe Michael M Chief Executive Officer Aug 26 '24 Buy 0.57 50,000 28,500 82,927 Aug 27 01:06 PM Grant Stuart M. 10% Owner Jul 02 '24 Buy 0.66 1,515,151 1,000,000 10,914,153 Jul 03 03:18 PM Grant Stuart M. 10% Owner Mar 28 '24 Buy 0.98 100,000 98,000 5,430,715 Mar 28 03:50 PM Grant Stuart M. 10% Owner Mar 19 '24 Buy 1.23 50,000 61,500 5,330,715 Mar 20 05:44 PM Grant Stuart M. 10% Owner Mar 08 '24 Buy 1.58 10,717 16,911 5,280,715 Mar 11 08:11 AM Rowe Michael M Chief Executive Officer Dec 04 '23 Buy 1.36 4,890 6,650 32,927 Dec 05 04:54 PM Strahlman Ellen R Director Sep 29 '23 Buy 1.68 4,820 8,098 75,113 Oct 02 10:04 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite